ACT Brief: Real-Time Data Harmonization Infrastructure, Modern Trial Payments, and SCLC Drug Confirmatory Failure

This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.

• In part five of his interview, Raj Indupuri of eClinical Solutions explained why organizations that build infrastructure capable of harmonizing clinical and real-world data in real time will be best positioned for the continuous, data-driven regulatory environment now emerging. Real-time data integration enables sponsors to move from retrospective evidence assembly to concurrent validation during development.
• In a new contributed article, experts from PayQuicker discussed how clinical trials can modernize participant payments by borrowing from gig economy approaches—offering flexible payout options and faster fund access instead of prepaid cards and checks. Modern payment platforms reduce administrative burden on sites, improve participant retention by removing friction, and enable global reach without adding compliance complexity through centralized fraud and privacy controls.
• Jazz Pharmaceuticals announced that Zepzelca failed to meet the primary endpoint of overall survival in the Phase III Lagoon confirmatory trial for second-line relapsed small cell lung cancer. The accelerated approval in that indication is now at risk, though the drug's full approval for first-line maintenance treatment with immunotherapy remains unaffected based on separate Phase III data showing 46% reduction in disease progression or death.

That's all for today's ACT Brief. Be sure to stay tuned to our website and LinkedIn this week for exclusive coverage of the DIA Global Annual Meeting in Philadelphia.